



Partnership for  
Quality Measurement

# Consensus Standards Approval Committee (CSAC)

Fall 2022 Measure Evaluation Meeting

July 24, 2023

*The analyses upon which this publication is based were performed under Contract Number 75FCMC23C0010, entitled, "National Consensus Development and Strategic Planning for Health Care Quality Measurement," sponsored by the Department of Health and Human Services, Centers for Medicare & Medicaid Services.*

# Welcome



# Welcome to Today's Meeting!



- Housekeeping reminders:
  - The system will allow you to mute/unmute yourself and turn your video on/off throughout the event
  - Please raise your hand and unmute yourself when called on
  - Please lower your hand and mute yourself following your question/comment
  - Please state your first and last name if you are a Call-In-User
  - We encourage you to keep your video on throughout the event
  - Feel free to use the chat feature to communicate with Battelle staff
- If you are experiencing technical issues, please contact the project team via chat on the virtual platform or at [PQMsupport@battelle.org](mailto:PQMsupport@battelle.org)


# Using the Zoom Platform



The screenshot shows a Zoom meeting interface. At the top, there are two video thumbnails: 'Host' on the left and 'Attendee 2' on the right. Below them is a large 'Attendee' video thumbnail. At the bottom, there is a toolbar with various icons. Three numbered callouts are present: 1. A white circle with the number '1' is positioned over the bottom toolbar. 2. A white circle with the number '2' is positioned over the 'Participants' button in the bottom toolbar. 3. A white circle with the number '3' is positioned over the 'Reactions' menu, specifically the 'Raise Hand' option.

- 1 Click the lower part of your screen to mute/unmute, start, or pause video
- 2 Click on the participant or chat button to access the full participant list or the chat box
- 3 To raise your hand, select the raised hand function under the reactions tab

# Using the Zoom Platform (Phone View)




- 1 Click the lower part of your screen to mute/unmute, start or pause video
- 2 Click on the participant button to view the full participant list
- 3 Click on “more” button to (3A) view the chat box, (3B) show closed captions, or to (3C) raise your hand. To raise your hand, select the raised hand function under the reactions tab



3B

3C



# CSAC Project Team



- Nicole Brennan, MPH, DrPH, Executive Director
- Brenna Rabel, MPH, Deputy Director
- Quintella Bester, PMP, Senior Program Manager
- Matthew Pickering, PharmD, Principal Quality Measure Scientist
- Amanda Overholt, MPH, Social Scientist III
- Jessica Ortiz, MA, Social Scientist II
- Rajbir Kaur, MPH, Social Scientist I
- Elena Hughes, MSc, Social Scientist I

# Agenda



- Welcome and Review of Meeting Objectives
- Roll Call and Disclosures of Interest
- CSAC Measure Review Procedure
- Review of the Consent Calendar Measures
- Lunch
- Discussion and Voting of Candidate Non-consent Calendar Measures
- Opportunity for Public Comment
- Next Steps
- Adjourn

# Roll Call and Disclosures of Interest





# CSAC Members



- **John Bulger, DO, MBA (Chair)**
- **Edward Septimus, MD (Vice Chair)**
- Ramsey Abdallah, MBA, CPHQ, PMP
- Elizabeth Albers, MD
- Dan Culica, MD, MA, PhD
- Dana Cyra, MA, CPHQ (*inactive*)
- Melissa Danforth
- Karen Johnson, PhD
- Kevin Kavanagh, MD, MS, FACS
- Rebecca Kirch, JD
- Gerri Lamb, PhD, RN, FAAN
- Sean Morrison, MD (*inactive*)
- Kelly Nedrow, JD
- Jeffrey Susman, MD
- Adam Thompson, MPH

# CSAC Measure Review Procedure and Test Vote



# CSAC Procedures: *Consent Calendar 1*

## Prior to the CSAC Meeting



- Battelle staff sends the consent calendar to the CSAC for review and consideration of the measures on the consent calendar.
- The CSAC may submit a request to pull a measure from the consent calendar, along with a *clear and compelling rationale* that is based on the key considerations criteria (page 3 of CSAC Discussion Guide).
  - The request is submitted to Battelle staff and to the CSAC chair and vice chair.
  - If a measure is pulled for discussion, Battelle staff will notify the measure developer/steward and the respective standing committee co-chairs.
  - The CSAC member who requested to pull the measure will serve as the lead discussant of the measure during the CSAC meeting.
- If a measure is pulled for discussion, Battelle staff will update the meeting materials to reflect any changes and resend the materials to the CSAC prior to the CSAC meeting.

# CSAC Procedures: *Consent Calendar 2*

## Criteria



**Measures not discussed must meet all of the following key considerations criteria:**

1. Received 80 percent or greater passing votes for overall suitability for endorsement
2. No process concern(s) identified that may have affected the endorsement decision of a measure
3. No reconsideration request was received for either the standing committee's or the CSAC's adjudication
4. The standing committee accepted the Scientific Methods Panel's (SMP) ratings (i.e., did not overturn the SMP's decision), if applicable
5. No new information was received through public comment that was not available or discussed during the standing committee's measure evaluation meeting that is conflicting to the standing committee's recommendation(s)
6. The measure was not pulled for discussion by a CSAC member
7. No additional concerns were identified that require CSAC discussion (Note: These concerns should reside within the [purview of the CSAC](#))

# CSAC Procedures: *Consent Calendar 3*

## During the CSAC Meeting



- For the measure evaluation discussions, Battelle staff will first provide an overview of the measures within the consent calendar, noting any measures that were pulled for discussion prior to the meeting.
- For the measures that remained on the consent calendar (i.e., were not pulled by the CSAC in advance of the meeting), the standing committee's endorsement recommendations are upheld by the CSAC for these measures, and they will not be discussed during the CSAC meeting.
- The CSAC chair or vice chair then opens the floor for public comment related to the measures on the consent calendar.

# CSAC Procedures: *Non-consent Calendar Measures*



## During the CSAC Meeting

- After the review of the consent calendar, the CSAC proceeds to review and vote on the measures that require discussion, as they do not meet all of the key considerations criteria
  - For these measures, Battelle staff and the respective standing committee co-chairs present the standing committee's deliberations and recommendations for each measure
  - The CSAC has an opportunity to ask clarifying questions and then moves to vote on each measure separately.
- CSAC members then vote on the acceptance of the standing committee's recommendation(s)
  - Accept the standing committee's recommendation (i.e., to endorse or not endorse)
  - Do not accept the standing committee's recommendation and return the measure to the Committee for reconsideration

# Review of the Consent Calendar Measures



# Fall 2022 Measures Under Review



Measure Summary	Number of Measures	New and Maintenance
Total for fall 2022 cycle	28	<ul style="list-style-type: none"><li>• 16 New</li><li>• 12 Maintenance</li></ul>
Consent calendar measures	16	<ul style="list-style-type: none"><li>• 7 New</li><li>• 9 Maintenance</li></ul>
Non-consent calendar measures	12	<ul style="list-style-type: none"><li>• 9 New</li><li>• 3 Maintenance</li></ul>
Measures pulled for discussion prior to CSAC meeting	0	<ul style="list-style-type: none"><li>• 0 New</li><li>• 0 Maintenance</li></ul>



# Review of the Consent Calendar Measures

*Screenshare CSAC Discussion Guide*



# Lunch Break

*CSAC Reconvenes at  
12:00 pm ET*



# Discussion and Voting of Candidate Non-consent Calendar Measures



# Overarching Issues



- **Linking Cost and Quality Measures**

- During the review of CBE #3474, the committee expressed the need for correlation analyses between cost measures to quality measures, as the absence of a clearly defined relationship between quality and cost makes it challenging for patients to truly know whether lower cost is better. Current endorsement criteria do not require cost measures to be correlated to a quality indicator.

- **Risk Adjustment of Social Risk Factors**

- Committee concerns continue regarding the accuracy of cost and outcome measures without appropriate adjustment for social risk factors. This was evident with the review of CBE #3474

- **Lack of Evidence Demonstrating Improved Outcomes**

- Several measures (CBE #3716, CBE #3735, CBE #3722, CBE #3725, CBE #3572, CBE #3707, CBE #3729) reviewed this cycle did not pass on evidence due to a lack of strong, empirical evidence that the measure leads to improved outcomes. The committees reviewing these measures recognized the importance of the measures, but expressed the need for more evidence to support them.

# Standing Committee Summaries:

## Cardiovascular



### Non-consent Calendar Measures **Not** Recommended for Endorsement:

- **#3716** CVD Risk Assessment Measure – Proportion of Pregnant/Postpartum Patients That Receive CVD Risk Assessment With a Standardized Tool (University of California, Irvine) New
  - Evidence: H-0; M-3; L-4; I-9 (denominator = 16) (19.0%, No Pass)
- **#3735** CVD Risk Follow-up Measure - Proportion of patients with a positive CVD risk assessment who receive follow-up care (University of California, Irvine) New
  - Evidence: H-0; M-1; L-2; I-15 (denominator = 18) (6.7%, No Pass)
    - Insufficient Evidence With Exception: Insufficient Evidence With Exception – 2; No exception – 16 (denominator = 18) (11.1%, No exception)
- **Key Considerations Criteria Not Met:**
  - The measures did not receive 80 percent or greater passing votes for overall suitability for endorsement, as the measures did not pass evidence, a must-pass criterion (Measures #3716, #3735)

# Standing Committee Summaries:

## *All-Cause Admissions and Readmissions*



### Non-consent Calendar Measure **Not** Recommended for Endorsement:

- **#3474** Hospital-Level, Risk-Standardized Payment Associated With a 90-Day Episode of Care for Elective Primary Total Hip and/or Total Knee Arthroplasty (Yale New Haven Health Services Corporation – Center for Outcomes Research and Evaluation/Centers for Medicare & Medicaid Services [CMS]) [Maintenance]
  - *Validity: H-0; M-7; L-7; I-1 (denominator = 15) (47.0%, No Pass)*
- **Key Considerations Criteria Not Met:**
  - The measure did not receive 80 percent or greater passing votes for overall suitability for endorsement, as the measure did not pass on validity, a must-pass criterion (Measure #3474)

# Standing Committee Summaries:

## *Patient Experience and Function*



### Non-consent Calendar Measures Recommended for Endorsement:

- **#2958** Informed, Patient-Centered (IPC) Hip and Knee Replacement Surgery (Massachusetts General Hospital) [Maintenance]
  - *Overall Suitability for Endorsement: Y-10; N-3 (denominator = 13) (76.9%, Pass)*
- **#2962** Shared Decision-Making Process (Massachusetts General Hospital) [Maintenance]
  - *Overall Suitability for Endorsement: Y-10; N-3 (denominator = 13) (76.9%, Pass)*
- **#3720** Patient-Reported Fatigue Following Chemotherapy among Adults with Breast Cancer (Purchaser Business Group on Health) [New]
  - *Overall Suitability for Endorsement: Y-8; N-4 (denominator = 12) (66.7%, Pass)*
- **Key Considerations Criteria Not Met:**
  - The measures did not receive 80 percent or greater passing votes for overall suitability for endorsement (Measures #2958, #2962, #3720)

Break

*CSAC Reconvenes at  
2:15 pm ET*





# Standing Committee Summaries: *Geriatrics and Palliative Care*



## Non-consent Calendar Measures **Not** Recommended for Endorsement:

- **#3672** Ratio of Observed Over Predicted Rates for Diagnosis of Dementia (University of Southern California [USC]) [New]
  - *Evidence: H-0; M-1; L-12; I-3 (denominator = 16) (6.3%. No Pass)*
- **#3707** Ratio of Observed Over Predicted Rates for Diagnosis of Mild Cognitive Impairment (USC) [New]
  - *Evidence: H-1; M-0; L-8; I-6 (denominator = 15) (6.7%, No Pass)*
- **#3729** Ratio of Observed Over Predicted Rates for Diagnosis of Cognitive Impairment of Any Stage (USC) [New]
  - *Evidence: H-0; M-2; L-14; I-0 (denominator = 16) (12.5%, No Pass)*
- **Key Considerations Criteria Not Met:**
  - The measures did not receive 80 percent or greater passing votes for overall suitability for endorsement, as the measures did not pass on evidence, a must-pass criterion (Measures #3672, #3707, #3729)

# Standing Committee Summaries:

## *Renal*



### Non-consent Calendar Measures **Not** Recommended for Endorsement:

- **#3719** Prevalent Standardized Waitlist Ratio (PSWR) (University of Michigan Kidney Epidemiology and Cost Center/CMS) New
  - *Validity: H-1; M-4; L-11; I-1 (denominator = 17) (29.4%, No Pass)*
- **#3722** Home Dialysis Rate (Kidney Care Quality Alliance [KCQA]) New
  - *Evidence: H-0; M-3; L-7; I-2 (denominator = 12) (25.0%, No Pass)*
- **#3725** Home Dialysis Retention (KCQA) New
  - *Evidence: H-0; M-4; L-7; I-2 (denominator = 13) (30.7%, No Pass)*
- **Key Considerations Criteria Not Met:**
  - The measures did not receive 80 percent or greater passing votes for overall suitability for endorsement, as the one measure did not pass on validity, a must-pass criterion (Measure #3719) and two measures did not pass on evidence, a must-pass criterion (Measures #3722, #3725)

# Opportunity for Public Comment



# Next Steps



# CSAC Next Steps



- **Appeals Period:** August 1 to August 30, 2023
- **Technical Reports:** September/October 2023
- **Spring 2023 CSAC:** December 6 – 7, 2023

# E&M Contact Information



- **E&M Webpage:** <https://p4qm.org/endorsement>
- **Project Email Address:** [PQMsupport@battelle.org](mailto:PQMsupport@battelle.org)

Thank You!





Partnership for  
Quality Measurement

powered by

***BATTELLE***